estradiol valerate / Generic mfg. - LARVOL DELTA

Estrogens hypersensitivity syndrome in endometriosis. (PubMed, Endocr Regul) - "After blood sampling to determine the baseline levels of Hsp90α, the patients were prescribed a single oral dose of estradiol valerate 2 mg tablet...The increase in Hsp90α plasma level of more than 30% within 6 h after the test-load is a specific criterion for estrogen hypersensitivity syndrome in endometriosis. Further investigation including other nosological forms (myoma, adenomyosis, endometrial hyperplasia) is required."

Biomarker • Journal • Endometriosis • Gynecology • Immunology • Solid Tumor • Uterine Leiomyoma • Women's Health • CDC37 • HSP90AA1

The Effectiveness of Pelvic Floor Physiotherapy on Endometrial Thickness during Embryo Transfer in Infertile Women: A Systematic Review and Meta-analysis. (PubMed, Int J Fertil Steril) - "This study analyzed randomized controlled trials (RCTs) assessing pelvic floor physiotherapy effects on endometrial thickness in infertile women, compared to routine treatments such as estradiol valerate tablets with vaginal progesterone gel, and oral Progynova. Critically, this conclusion is based on low to very low-quality evidence, limiting confidence in the observed benefits. Furthermore, the effect of physiotherapy on uterine arterial resistance and pulsatility indices is currently undetermined due to insufficient data (Prospero ID: CRD42023442310)."

Journal • Retrospective data • Review • Endometriosis • Gynecology • Infertility • Oncology • Sexual Disorders

Endometrial Response in Polyendocrine Metabolic Ovarian Syndrome (PMOS) Treated With Letrozole Alone or With Added Estradiol Valerate (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: CMH Kharian Medical College | Not yet recruiting ➔ Completed

Trial completion • Polyendocrine Metabolic Ovarian Syndrome

Effects of Estrogen Therapy on Lipid Metabolism and Insulin Sensitivity in Hypogonadal Women (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Khyber Medical University Peshawar

New trial • Endocrine Disorders • Metabolic Disorders

Tenghuang Jiangu Capsules promote Treg cell differentiation in rat model of postmenopausal osteoporosis via modulation of SIRT1-mediated JAK3/STAT5 pathway (PubMed, Zhongguo Zhong Yao Za Zhi) - "The successfully modelled rats were randomized into model, positive control(estradiol valerate, 0.09 mg·kg~(-1)), high-dose(0.36 g·kg~(-1)) TJC, medium-dose(0.18 g·kg~(-1)) TJC, low-dose(0.09 g·kg~(-1)) TJC, and SIRT1 inhibitor(EX-527, 1 mg·kg~(-1)) groups(10 per group). Simultaneously, it increased the number of Treg cells in the femoral bone marrow(P<0.01), upregulated the mRNA level of OPG and the protein levels of SIRT1, STAT5, TGF-β, p-JAK3/JAK3, and OPG(P<0.05 or P<0.01), and downregulated the mRNA and protein levels of RANKL(P<0.01) in the femur of PMOP rats. The above results indicated that TJC could maintain bone homeostasis in PMOP rats by promoting Treg cell differentiation via modulation of SIRT1-mediated JAK3/STAT5 pathway."

Journal • Preclinical • Osteoporosis • Rheumatology • FOXP3 • IL10 • JAK3 • STAT5 • TGFB1 • TNFRSF11B • TNFSF11

Natural estrogens: the new reference in contraception. An Italian expert opinion paper. (PubMed, Expert Opin Pharmacother) - "The replacement of synthetic ethinyl estradiol (EE) with natural estrogens - estradiol (E2), estradiol valerate (E2V), and estetrol (E4) - represents a significant advancement in improving the tolerability, safety, and acceptability of hormonal contraception...Their incorporation into clinical guidelines as first-line options requires comprehensive awareness among healthcare providers and broader access for users. Further lines of research may focus on pharmacological optimization and long-term safety across diverse populations as in women with comorbidities to fully realizing their clinical wide potential."

Journal • Cardiovascular

PCOS-like phenotype in rats after intrauterine EV exposure: puberty and adulthood. (PubMed, Endocr Connect) - "Estradiol valerate (EV) is widely used to induce PCOS-like phenotypes; however, its potential role in disrupting early development and altering postnatal reproductive function remains unknown...In adult life, these alterations had progressed into a PCOS-like phenotype, characterized by body weight gain, increased testosterone levels, acyclicity, anovulation, and the presence of follicular cysts. These findings indicate that prenatal exposure to EV is sufficient to induce a progressive reproductive phenotype that resembles PCOS in adulthood."

Journal • Preclinical • CNS Disorders • Developmental Disorders • Endocrine Disorders • Polyendocrine Metabolic Ovarian Syndrome • Psychiatry

A Fluorescent Probe for Carboxylesterases Detection in Estradiol Valerate-Treated Inflammation Alleviation. (PubMed, J Fluoresc) - "By the construction of the basic correlation between the CE level and the fluorescence signal intensity, PIPM-CE achieved imaging the EV-treated inflammation alleviation on both the rational therapeutical treatment and the avoidance of overdose-caused disorder. This work was meaningful for the precise monitoring of the hormone therapies."

Journal • Inflammation

Effect of Estradiol Pretreatment on Follicular Synchronization and IVF Outcomes in Women With Polycystic Ovary Syndrome Undergoing ICSI Using GnRH Antagonist Protocol (clinicaltrials.gov) - P=N/A | N=61 | Completed | Sponsor: Cairo University

New trial • Polyendocrine Metabolic Ovarian Syndrome

Progesterone Levels on the Day of Frozen-thawed Embryo Transfer in Artificial Cycles with Vaginal Progesterone Do not Predict Clinical Pregnancy: a Prospective Study. (PubMed, Reprod Sci) - "This prospective cohort study included 235 patients who underwent FET following AEP cycles with estradiol valerate and vaginal micronized P. All patients received either blastocyst- or cleavage-stage embryos derived from their own oocytes, without preimplantation genetic testing for aneuploidies. In the multivariate logistic regression model, this difference was not statistically significant (OR = 2; 95% CI: 0.9-5). Routine monitoring of serum P levels on the day of embryo transfer in AEP cycles using vaginal micronized P is not justified, as serum P levels do not effectively predict CP outcomes in cycles using autologous oocytes."

Journal

Prospective, Open-Label, and Three-Arm Investigator-Initiated Study to Compare the Efficacy and Safety of Three Estradiol Treatment Protocols for Endometrial Preparation in Frozen Embryo Transfer (FET) Cycles. (PubMed, Cureus) - "Endometrial thickness, endometrial volume, and serum estradiol levels on progesterone‑start day were measured. Conclusions Estradiol hemihydrate, whether administered orally or vaginally, demonstrated non‑inferior efficacy to oral estradiol valerate for endometrial preparation in FET cycles. Vaginal estradiol hemihydrate achieved adequate endometrial development at significantly lower doses overcoming the barriers of first pass metabolism and minimizing the safety concerns of thrombo-embolism."

Journal • Cardiovascular

UTERINE-PRESERVING ROBOTIC RESECTION OF A CHALLENGING SUBMUCOSAL FIBROID UNDER ULTRASOUND GUIDANCE. (PubMed, J Minim Invasive Gynecol) - "For challenging submucosal myomas where hysteroscopic resection may be incomplete or high-risk, an ultrasound-guided robotic platform allows for precise enucleation and robust reconstruction. This approach ensures complete preservation of endometrial integrity, optimizing reproductive outcomes for patients seeking uterine preservation."

Journal • Gynecology • Oncology • Pediatrics • Solid Tumor • Thermal Injury • Uterine Leiomyoma

Therapeutic Effects of Adipose-Derived Mesenchymal Stem Cell Exosome like Nanovesicles on Granulosa Cell Function in a Mouse Model of Polycystic Ovarian Syndrome: Involvement of FOXO3, Map1lc3b, SF-1 Genes. (PubMed, Reprod Sci) - "PCOS was induced via a single subcutaneous injection of estradiol valerate...Gene expression analysis also showed a marked up-regulation of FOXO3, along with increased Map1lc3b and SF-1 levels. Accordingly, AD-MSCs-Exosome like nanovesicles at optimum concentration exert regenerative effects on PCOS-induced ovarian dysfunction, which emphasizes the necessity for precise dose selection to achieve maximal therapeutic efficacy as a promising cell-free strategy for PCOS treatment."

Journal • Preclinical • Anesthesia • Inflammation • Polyendocrine Metabolic Ovarian Syndrome • CD9 • FOXO3 • MAP1LC3B

The effect of platelet-rich plasma extracellular vesicles (PRP-EVs) on the expression of BECN1, CYP19a1, and BMP6 as critical genes related to autophagy and steroidogenesis in ovarian granulosa cells of polycystic ovarian syndrome (PCOS) mouse model. (PubMed, Tissue Cell) - "Overall, our study suggests that PRP-EVs can be suggested as a promising biopharmaceutical source for PCOS conditions as a novel therapeutic option. Despite this advance, purifying EVs, quantifying EVs by particle size, providing safety, and determining fertility outcomes hinder the clinical application of PRP-EVs."

Journal • Preclinical • Polyendocrine Metabolic Ovarian Syndrome • BECN1 • BMP6 • CD63 • CYP19A1

Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. (clinicaltrials.gov) - P1 | N=316 | Suspended | Sponsor: ART Fertility Clinics LLC | Trial completion date: Dec 2025 ➔ Dec 2026 | Recruiting ➔ Suspended | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Trial suspension • Infertility • Sexual Disorders

Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle. (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: ART Fertility Clinics LLC | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Infertility • Sexual Disorders • IL4

Bilateral Thalamic Infarction Secondary to Deep Cerebral Venous Thrombosis: A Diagnostic Challenge Associated With Hormonal Therapy. (PubMed, Cureus) - "We report the case of a 56-year-old female with a history of chronic oral estradiol valerate and levonorgestrel use for hormone replacement therapy, who presented with acute neurological impairment, including deep somnolence and temporospatial disorientation. The patient was treated with therapeutic doses of enoxaparin, showing remarkable clinical improvement and regaining full orientation within eight days. DCVT must be considered a primary differential diagnosis in patients with impaired consciousness and symmetrical bilateral thalamic lesions, as early recognition of procoagulant risk factors and immediate anticoagulation are decisive in preventing permanent sequelae."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Thrombosis • Vascular Neurology

Effects of different durations of high-intensity interval training or continuous training with/without metformin on lipid profile and malondialdehyde level in a rat model of polycystic ovary syndrome. (PubMed, Vet Res Forum) - "The PCOS was induced by a single intra-muscular injection of 2.00 mg kg-1 estradiol valerate. Finally, serum malondialdehyde level decreased in groups received exercise intervention alone or combined with MET compared to the PCOS group. These findings revealed that HIIT and CT with longer periods with/without MET can lead to improvement of lipid profile and malondialdehyde level of PCOS patients."

Journal • Preclinical • Dyslipidemia • Endocrine Disorders • Polyendocrine Metabolic Ovarian Syndrome

Approach to Persistently Non-Suppressed Testosterone in A Transfeminine Adult (ENDO 2026) - "GAHT was initiated in 5/2023 through an online service, beginning with oral estradiol for one year before transitioning to injectable estradiol valerate 5 mg weekly with spironolactone 100 mg daily. This case underscores the importance of a structured approach to persistent testosterone elevation in transfeminine patients, as described by Maheshwari et al. (2021), and highlights the need for vigilance for germ cell tumors even when feminization is progressing and gonadotropins are suppressed."

Clinical • Embryonal Tumor • Germ Cell Tumors • Testicular Seminoma

A Novel ARX Mutation in A Congenital Hypogonadotropic Hypogonadism and Graves' Disease: A Case Report (ENDO 2026) - "She was started on estradiol valerate and methimazole. Clear genotype–phenotype associations in ARX-related disorders have yet to be established. This case highlights the broad clinical spectrum of ARX-associated disease and underscores that genes traditionally implicated in neurodevelopmental disorders can present with isolated CHH. It expands the current understanding of CHH and provides a basis for future research into the role of the ARX gene in reproductive endocrinology."

Case report • Clinical • CNS Disorders • Developmental Disorders • Endocrine Disorders • Grave’s Disease • Infertility • Mental Retardation • Rare Diseases • Sexual Disorders • Women's Health

Revisiting Injectable Estradiol Valerate Dosing for Gender-Affirming Hormone Therapy: A Retrospective Cohort Review. (PubMed, Endocr Pract) - "Despite using injectable estradiol doses on the lower end of the current guidelines, most estradiol concentrations outside the range suggested by the Endocrine Society (100-200 pg/mL) were above the suggested range. The majority of patients obtained physiologic estradiol concentrations, as approximated by lab reference ranges. Guidelines for physiologic estradiol concentrations should recommend lower doses for injectable estradiol valerate."

Journal • Retrospective data

Tiao-Jing-Cu-Yun Acupuncture combined with estradiol in the treatment of patients with thin endometrium undergoing hormone replacement therapy for frozen embryo transfer: a randomized controlled trial. (PubMed, Front Med (Lausanne)) - "A total of 92 infertility patients with endometrial thickness <7 mm undergoing AC-FET at our hospital were enrolled and randomly assigned to two groups: the control group (n = 45) received oral estradiol valerate-based hormone replacement therapy combined with sham acupuncture; the Intervention Group (n = 47) received the same HRT regimen combined with Tiao-Jing-Cu-Yun Acupuncture administered every other day starting from menstrual cycle day 2-3 until the day before embryo transfer...After treatment, the Intervention Group showed a significantly greater increase in progesterone (P) level, endometrial thickness and volume, and a more pronounced decrease in endometrial resistance index (RI) and pulsatility index (PI) compared to the control group (all p < 0.05)...The combination of Tiao-Jing-Cu-Yun Acupuncture with standard hormonal therapy can effectively improve endometrial receptivity in patients with thin endometrium and significantly enhance the clinical..."

Clinical • Journal • Infertility • Sexual Disorders

Comparison of two menopausal hormone therapy regimens in managing menopausal symptoms: a retrospective study. (PubMed, BMC Womens Health) - "Femoston and Climen provide comparable short-term menopausal symptom relief. The more favorable lipid profile with Femoston, particularly its HDL-C benefit, may inform individualized regimen selection, especially in women without indications for antiandrogenic therapy. Prospective studies with longer follow-up are warranted to evaluate hard cardiovascular endpoints."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Insomnia • Sleep Disorder

Integrated transcriptomic and proteomic profiling implicates prostaglandin-nitric oxide network dysregulation in uterine microcirculatory impairment in primary dysmenorrhea. (PubMed, Front Immunol) - "A PD model was established in 12 female Sprague-Dawley rats (control, n = 6; PD, n = 6) using estradiol valerate, repeated cold exposure, and oxytocin stimulation...PD rats also showed decreased plasma NO and β-endorphin (β-EP) levels, altered estradiol (E2) and progesterone (P) levels, uterine histopathological injury, and coagulation disturbance, consistent with impaired vascular regulation and endogenous analgesic capacity...These findings support a systems-level model in which prostaglandin imbalance, coagulation-associated microcirculatory dysfunction, and dysregulated arginine-proline metabolism may jointly contribute to uterine ischemia and pain sensitization in PD. Our study proposes a refined molecular framework for PD pathogenesis and highlights the arginine-NO axis as a potential therapeutic target tworthy of future investigation."

Journal • Cardiovascular • Gynecology • Pain • Women's Health

Estrogen therapy for menopausal hair loss: A systematic review (SID 2026) - "While 2 uncontrolled trials reported increases in hair count and caliber in women with female pattern hair loss (FPHL), comparative studies (including an RCT) indicated 17α-estradiol was outperformed by minoxidil and finesteride+minoxidil combinations...Estradiol valerate improved anagen:telogen ratios in a placebo-controlled trial, but serious gynecologic adverse events were reported, including 1 case of breast cancer (unclear causality) and 2 cases of endometrial hyperplasia...Overall, there is insufficient evidence to support the safety or efficacy of topical or systemic estrogen for hair loss in menopause. 1.Gupta et al., PMID 40318238 2.Grymowicz et al., PMID 32731328"

Review • Alopecia • Breast Cancer • Fibrosis • Immunology • Solid Tumor